Conversational AI for Rapid Vaccine Uptake: Engagement, Education, Safety Management & Insights

Panelists: 

  • Dr. Andrew Rut - CEO, MyMeds&Me
  • Richard Marcil - Chief Customer Officer, conversationHEALTH

Moderator:

  • Dr. Andree Bates - Eularis

Speaker:

Welcome my panelists today, Dr Andrew Rut CEO of MyMeds&Me and Richard Marcil Chief Customer Officer of conversationHEALTH.

Dr Andrew Rut is a trained physician specializing in Endocrinology and Genetics. He has held senior roles spanning Drug Discovery and Development within GSK working across USA, Europe, and Asia-Pacific. He was previously Head of Safety at GSK where he drove significant innovation and streamlining into the organization.

Richard Marcil is a C-level executive with 20 years of building brands and businesses in startup and multinational organizations, in North America and globally.  Prior to conversationHEALTH, Richard led a North American strategy agency focused on brand innovation and digital transformation, working with companies like Salesforce and Veeva. But at heart, Richard is an industry insider.  He was a founding executive at Silicon Valley-based biotech companies, and before that held a number of leadership roles across Johnson & Johnson businesses.


Today is an interesting topic - Conversational AI for Rapid Vaccine Uptake: Engagement, Education, Safety Management & Insights where we will discuss the development of vaccines, it's been such a race to get the vaccine to market. So, stage two of the relay race begins where up to 7 billion people will be vaccinated. 

Speaker: 

We have to make sure the right information is shared and make sure it trumps the rules out there on the web, so that we can make an appointment to a customer.  The next one I know which light is coming. What can we do as an industry I think I can look at as we look at 2021 is funny because nobody's to age. me after her ready for fundamental change, and we need to discuss some service because there's no doubt products being launched. Therefore, even nations in the active vaccine and based on things like age vary efficacy and safety findings with some of the vaccines, we are information, the information essentially the first phase of our clinical experiment has to consume the product but also the safety profiles across those groups because we just we just haven't had the sample sizes needed.

Speaker: 

Protocol across our population that we do not practically because information should inform vaccinations subjects. Richard, what do you think in terms of the process such obviously customers most manufacturing providers and again, manufacturers product success false information is yes. So there's tremendous history. Historical. Richard says, information is lost as a result of trials which teach

Speaker:

As consumers we have within our industry that was you know, just the stereotypes that the younger group uses social media right now is that it's not the reality. Anyone can be searching vaccine information online regardless of your age. The engagement that we need to solve technology, is it the technology itself comfortable with a conversation you know, face to face is open the next piece of information resources and education I believe a lot of manufacture makers are trained to you know, it's, it's a lot different inside of video chat or something like know that this morning, you know, 30% of us going to be able to see and feel engaged in that situation. So it's not just technology, it's training. And we do need to make sure that interaction which we and the positions become more comfortable there's an emerging it's in the last year that allows me to access all the public health care professionals to get new information. Real World we've gone back to the public, to healthcare professionals, to government agencies in real time, so they don't go to Facebook and get it. Feel free to also think the sequencing of this early assembly, not having a choice getting the age of 14 year old to 20 year olds, there's going to be a significant hesitancy and others messaging is critical for these groups to demonstrate significant hesitancy so they need to address them. Absolutely. According to the differential, patient population, risk of getting severe risk to the benefit risk ratio. You can't say something if you don't collect the data. That's a great segway into data because we just talked about the data pre vaccination. So why collecting so much data pre and post vaccination is so important.

Speaker:  

I am a proponent of that within social media. It takes time and is tremendously awesome. To build a robust social media community, be patient, make sure they have access to your share. Because credibility is actually neutral, to negative misinformation that's out there. And it's going to be much by the person reading it, instead of Oh, company, ABC. but with data, risk profile, different drugs all those factors, we know that influence adverse events, we have to collect that data. 

Speaker:   

If we're having vaccines or 500,000 in the UK, so let's say and let's say we are reporting reports every day caregivers, health professionals, safety systems, professionals struggling a lot of hysteria. Most consumers, most physicians are digital. Hey, can I use extra consideration when comorbidity content or product information has complex patient cases? insurance issues. And by the same token for that same consumer

Speaker: 

Sometimes when that happens to someone, it's not like a pain for patients. They were just sharing information. being too long. As you said, it's just a little bit bigger than uncertified sources. We have lifetime contacts, our service and our network resources for consumers or patients. access to credit is hard. But anything we can do to facilitate in line with what there's an opportunity here.

Speaker:  

Okay. Really makes it before that, I actually, this is something from my perspective, I think increasingly competitors, we can really learn, I think there's diversity there they're very, super powerful. They do. I can almost do the other pieces like old technology solutions. improvement mindset, right? just gets better. Whether it's just minutes ago, imagine it. Patients that license industry without data resources haven't been updated. We struggled with saying that the last thing is really powerful. And she looked into this specifically for simplicity. I'm sure it is what it is. As much as any Google is to this ruthless efficiency,


Speaker:

What do I do now? To get information is critical. I think that's about it, what might look like and how to minimize empathy. virtualized the speed at which we get the insights from the data future, adopters could go to Dr. Google information accessible, etc. that's starting to happen. See, the doctors have much less time to do the research. And with Amazon, we've seen companies trying to do this. And it does feel like COVID it's been an accelerator for them to compete almost directly out there, especially when is to share commercialization they have to be seen the public has to communicate the vaccinations progress vaccination, maximum information several different vaccines vaccine DNA vaccine is coming forward with the protein vaccine vaccine the COVID-19 vaccination program states what are the unrelated to vaccination claim to be able to compare next scale distribution pharma get. Once technology comes into play, particularly the suits everything we've just talked to etc trained individuals because there's so much so I believe vaccinations consistent patience patience vaccinations were structured rapidly responsive efficient digital information enabling edge recovery mostly for ecpa information consumption. 

Speaker: 

I was talking about it and it was an interesting conversation. Have a drug that gets sold products I am worried about because I do believe that, you know, early in the healthcare space, I believe that keeps on the horizon. You know, my question is, do you meet new people to partner with your company moving forward, regardless of the future. Just sort of think about exceptional customer experiences, but I guess any kind of customer support, which is in the meantime, y'all Yeah. Absolutely. It definitely. Normal.

Speaker:  

I think it's very clear.

Speaker:  

There is no comment moving forward, because I don't know of anyone that really thought this was gonna go find a lot of folks. You know for at least the first couple weeks, this is temporary work. We have to watch for 20 we will get 20 maybe, but we will never go back to watching 202.

Speaker: 

This is new drugs rolling vaccination documents this is nothing new ACP systems are starting to care for these individuals. The entrepreneurial Financial Times and how technology is evolving as a catalyst for all the things that can happen in the healthcare landscape, however, was still on premise premises interoperability and results from tech companies, governments academics to drown out efficiency efficiency Why don't we use technology is trying to meet all the way that has been shaped probably not technology most global delivery and vaccinations is relatively global providers this industry to be a systems Improvement System capability to information making it accessible to compelling virtualized humans struggling to share those transfer analysis of transfer terms of opportunities which speaks of languages and technology providers how to ensure communication worked in different jurisdictions right now we have to appreciate technology digitizing virtualization is Two years ago, 10 years ago, countries over the course of the year training agents we can see multiple languages a physician versus English it's just you and your audience. It's interesting to see their development and capabilities of virtualization of their business and scale. It's interesting to see what it was to commercialize established technology capabilities that can be future applications COVID capacity capability digital transmission, basically, that's what would be your advice to the general public, you know, what it's subject is important. Data is just a bunch of serious embraces. Embrace powerful tool you will have so that's the first one embrace, embrace. Embrace dangerous, trusted technologies. Technology. Data Collection is the generation I want the data to be able to generate insights and manage vaccination or I think getting a reset to the wildly aggressive refresh existing skills versus just sheer transparency are specifically to healthcare practitioners around. great insights to share better, better health. Thank you so much.